Initial Studies

Initial Studies. The following human clinical studies to be performed by ViroPharma using the Compound during the Option Period: (a) a phase I tolerability study; (b) a phase I F19 MRI study; (c) a phase II dose ranging study, and (d) a phase I CYP 3A drug interaction study, in each case for an intranasal dosage form of the Product.